Initial treatment patterns over time for anaplastic oligodendroglial tumors Journal Article
| Authors: | Panageas, K. S.; Iwamoto, F. M.; Cloughesy, T. F.; Aldape, K. D.; Rivera, A. L.; Eichler, A. F.; Louis, D. N.; Paleologos, N. A.; Fisher, B. J.; Ashby, L. S.; Gregory Cairncross, J.; Urgoiti, G. B. R.; Wen, P. Y.; Ligon, K. L.; Schiff, D.; Ian Robins, H.; Rocque, B. G.; Chamberlain, M. C.; Mason, W. P.; Weaver, S. A.; Green, R. M.; Kamar, F. G.; Abrey, L. E.; Deangelis, L. M.; Jhanwar, S. C.; Rosenblum, M. K.; Lassman, A. B. |
| Article Title: | Initial treatment patterns over time for anaplastic oligodendroglial tumors |
| Abstract: | Anaplastic oligodendroglial tumors are rare neoplasms with no standard approach to treatment. We sought to determine patterns of treatment delivered over time and identify clinical correlates of specific strategies using an international retrospective cohort of 1013 patients diagnosed from 19812007. Prior to 1990, most patients received radiotherapy (RT) alone as initial postoperative treatment. After 1990, approximately 50 of patients received both RT and chemotherapy (CT) sequentially and/or concurrently. Treatment with RT alone became significantly less common (67 in 19801984 vs 5 in 20052007, P < .0001). CT alone was more frequently administered in later years (0 in 19801984 vs 38 in 20052007; P < .0001), especially in patients with 1p19q codeleted tumors (57 of codeleted vs 4 with no deletion in 20052007; P < .0001). Temozolomide replaced the combination of procarbazine, lomustine, and vincristine (PCV) among patients who received CT alone or with RT (87 vs 2 in 20052007). In the most recent time period, patients with 1p19q codeleted tumors were significantly more likely to receive CT alone (with temozolomide), whereas RT with temozolomide was a significantly more common treatment strategy than either CT or RT alone in cases with no deletion (P < .0001). In a multivariate polytomous logistic regression model, the following were significantly associated with type of treatment delivered: date (5-year interval) of diagnosis (P < .0001), 1p19q codeletion (P < .0001), pure anaplastic oligodendroglioma histology (P < .01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy. © 2012 The Author(s). |
| Keywords: | adolescent; adult; treatment outcome; aged; aged, 80 and over; middle aged; survival rate; retrospective studies; young adult; major clinical study; gene deletion; cancer localization; postoperative period; cancer combination chemotherapy; cancer radiotherapy; temozolomide; brain neoplasms; follow-up studies; dacarbazine; radiotherapy dosage; cohort analysis; vincristine; retrospective study; histology; lomustine; procarbazine; antineoplastic agents, alkylating; chromosomes, human, pair 19; oligodendroglioma; chromosomes, human, pair 1; international agencies; chemoradiotherapy; frontal cortex; 1p19q; pcv; oligoastrocytoma |
| Journal Title: | Neuro-Oncology |
| Volume: | 14 |
| Issue: | 6 |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2012-06-01 |
| Start Page: | 761 |
| End Page: | 767 |
| Language: | English |
| DOI: | 10.1093/neuonc/nos065 |
| PROVIDER: | scopus |
| PMCID: | PMC3367843 |
| PUBMED: | 22661585 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 2 July 2012" - "CODEN: NEURJ" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work